Literature DB >> 11131377

The course of laryngeal papillomatosis treated by endolaryngeal microsurgery.

V Uloza1.   

Abstract

Surgical excision of papillomas remains the mainstay of the management of laryngeal papillomatosis, as causal therapy is not yet available. Eighty-nine patients -32 with juvenile papillomatosis (JP) and 57 with adult papillomas (AP)-- underwent endolaryngeal microsurgery (EM) in our department during the last 15 years. The ENT-department in Kaunas serves most of the patients with laryngeal papilloma among the 3.85 million inhabitants of Lithuania. Therapeutic outcome was assessed as both the recurrence rate and the length of time between recurrences of papillomas in the follow-up period lasting at least 2 years. The recurrence rate was 71.9% (23 patients) in the JP group and 22.8% (13 patients) in the AP group. The interval between recurrences of papillomas ranged from 1 month to 10 years (mean 1.9 years) in the JP group and from 6 months to 9 years (mean 3.2 years) in the AP group. The number of EMs per patient ranged from 1 to 18 (mean 3.2) in the JP group and from 1 to 5 (mean 1.35) in the AP group. EM is a minimally invasive and safe technique which provides accurate removal of papillomas, although recurrence is often unavoidable. Prognosis for the disease therefore remains rather unpredictable.

Entities:  

Mesh:

Year:  2000        PMID: 11131377     DOI: 10.1007/s004050000273

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  7 in total

1.  [Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases. German version].

Authors:  V-A Papaioannou; A Lux; S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

2.  Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases.

Authors:  V-A Papaioannou; A Lux; S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

3.  Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels.

Authors:  Virgilijus Uloza; Vykintas Liutkevičius; Dalia Pangonytė; Viktoras Saferis; Vaiva Lesauskaitė
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-23       Impact factor: 2.503

4.  High recurrence rate in patients with juvenile-onset respiratory papillomatosis and its risk factors.

Authors:  Xiaoli Qu; Yang Xiao; Lijing Ma; Zijie Niu; Jun Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-20       Impact factor: 2.503

5.  Risk factors associated with severe recurrent respiratory papillomatosis.

Authors:  Muddaseer Khan; Tesuven K Naidu
Journal:  S Afr J Infect Dis       Date:  2019-11-20

Review 6.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

7.  HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis.

Authors:  Paul Stefan Mauz; Fabian Axel Schäfer; Thomas Iftner; Phillipp Gonser
Journal:  BMC Infect Dis       Date:  2018-07-24       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.